Key Insights Institutions' substantial holdings in Oruka Therapeutics implies that they have significant influence ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today. The company’s shares closed ...

Trends in International Mathematics and Science Study (TIMSS) revealed a concerning performance by South African students, ...

A United Kingdom upper tribunal has reversed a previous ruling that stopped the deportation of 43-year-old Nigerian Olutobi ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at ...

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...

Oruka Therapeutics has a 1 year low of $18.20 and a 1 year high of $53.88. The company has a market capitalization of $654.15 million, a price-to-earnings ratio of -2.98 and a beta of 0.87.

One of the runways at Vancouver International Airport will be closed for several days after a jet carrying Amazon packages overran it Tuesday morning. The Prime Air Boeing 767-300 operated by ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin ...